DNA adducts of cisplatin, transplatin and platinum-intercalating drugs
Leng, M.; Brabec, V.
Iarc Scientific Publications 125: 339-348
1994
ISSN/ISBN: 0300-5038 PMID: 7806323 Document Number: 436132
Document emailed within 1 workday
Related Documents
Mamenta, E.L.; Poma, E.E.; Kaufmann, W.K.; Delmastro, D.A.; Grady, H.L.; Chaney, S.G. 1994: Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines Cancer Research 54(13): 3500-3505Hannemann, J.; Baumann, K. 1988: Inhibition of lactate-dehydrogenase by cisplatin and other platinum-compounds: enzyme leakage of LDH is not a suitable method to measure platinum-compound-induced kidney cell damage in vitro Research Communications in Chemical Pathology and Pharmacology 60(3): 371-379
Johnson, S.W.; Swiggard, P.A.; Handel, L.M.; Brennan, J.M.; Godwin, A.K.; Ozols, R.F.; Hamilton, T.C. 1994: Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells Cancer Research 54(22): 5911-5916
Fichtinger-Schepman, A.M.; Vendrik, C.P.; van Dijk-Knijnenburg, W.C.; de Jong, W.H.; van der Minnen, A.C.; Claessen, A.M.; van der Velde-Visser, S.D.; de Groot, G.; Wubs, K.L.; Steerenberg, P.A. 1989: Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma Cancer Research 49(11): 2862-2867
Pouillart, P.; Beuzeboc, P.; Dorval, T.; Garcia-Giralt, E.; Jouve, M.; Palangie, T.; School, S. 1989: Advances in intercalating drugs Pathologie-Biologie 37(2): 159-160
Poirier, M.C.; Shamkhani, H.; Reed, E.; Tarone, R.E.; Gupta-Burt, S. 1992: DNA adducts induced by platinum drug chemotherapeutic agents in human tissues Progress in Clinical and Biological Research 374: 197-212
Ross, S.A.; Carr, C.A.; Brïet, J.W.; Lowe, G. 2000: Transfer of 4'-chloro-2,2':6',2"-terpyridine platinum(II) between human serum albumin, glutathione and other thiolate ligands. a possible selective natural transport mechanism for the delivery of platinum(II) drugs to tumour cells Anti-Cancer Drug Design 15(6): 431-439
Li, L.; Liu, X.; Glassman, A.B.; Keating, M.J.; Stros, M.; Plunkett, W.; Yang, L.Y. 1997: Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro Cancer Research 57(8): 1487-1494
Fracasso, M.E.; Apostoli, P.; Benoni, G.; Bonetti, A.; Griso, C.; Leone, R. 1987: Kinetics of platinum in cancer patients treated with cisplatin at different doses Drugs under Experimental and Clinical Research 13(6): 367-372
Berry, J.P.; Brille, P.; LeRoy, A.F.; Gouveia, Y.; Ribaud, P.; Galle, P.; Mathé, G. 1982: Experimental ultrastructural and X-ray microanalysis study of cisplatin in the rat: intracellular localization of platinum Cancer Treatment Reports 66(7): 1529-1533
Amlacher, R.; Winnefeld, K.; Schröter, H.; Hoffmann, H. 1988: Pharmacokinetics of platinum cytostatics after cisplatin-related equitoxic dosing to rats Die Pharmazie 43(11): 798-800
Gorbunova, V.A. 1989: Cisplatin (platidiam) and the prospects for using complex platinum compounds in the clinical chemotherapy of malignant tumors Voprosy Onkologii 35(3): 325-330
Bilgi, O.; Karagoz, B.; Alacacioglu, A.; Ozgun, A.; Tuncel, T.; Gokhan-Kandemir, E. 2010: Irinotecan and cisplatin vs. cyclophosphamide, doxorubicin, and vincristine as second-line treatment after platinum and etoposide in small-cell lung cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 15(2): 395
Nemoto, H.; Takeuchi, S.; Yoshizawa, Y.; Uemichi, O.; Sasaya, S.; Yamaguchi, M.; Makuuchi, M.; Midorikawa, T.; Sanada, Y.; Kumada, K.; Takizawa, K. 2001: Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(8): 1149-1153
Litterst, C.L.; Schweitzer, V.G. 1988: Covalent binding of platinum to renal protein from sensitive and resistant guinea pigs treated with cisplatin: possible role in nephrotoxicity Research Communications in Chemical Pathology and Pharmacology 61(1): 35-48
Endo, K.; Akamatsu, K.; Matsumoto, T.; Morikawa, K.; Koizumi, M.; Mitsui, H.; Koizumi, K. 1992: Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice Anticancer Research 12(1): 49-58
Huo, M.L.; Wang, Y.S.; Wang, P.; Xiang, Y.S.; Wang, J.G. 1986: Emesis induced by cisplatin and sulfato-1, sulfato-1,2-diaminocyclohexane platinum in dogs and their antiemetics Zhongguo Yao Li Xue Bao 7(2): 182-184
Waszkiewicz, K. 2001: About side effects of platinum drugs Postepy Higieny i Medycyny Doswiadczalnej 55(3): 387-406
Kuduk-Jaworska, J. 1984: Platinum complexes as potential antineoplastic drugs Postepy Higieny i Medycyny Doswiadczalnej 38(3): 281-322
Johnson, S.W.; Laub, P.B.; Beesley, J.S.; Ozols, R.F.; Hamilton, T.C. 1997: Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines Cancer Research 57(5): 850-856